Soluble CD146 is a novel marker of systemic congestion in heart failure patients: An experimental mechanistic and transcardiac clinical study

Mattia Arrigo, Quynh A. Truong, Duygu Onat, Jackie Szymonifka, Etienne Gayat, Heli Tolppanen, Malha Sadoune, Ryan T. Demmer, Ka Y. Wong, Jean Marie Launay, Jane Lise Samuel, Alain Cohen-Solal, James L. Januzzi, Jagmeet P. Singh, Paolo C. Colombo, Alexandre Mebazaa

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


BACKGROUND: Soluble CD146 (sCD146), is an endothelial marker with similar diagnostic power as natriuretic peptides in decompensated heart failure (HF). While natriuretic peptides are released by the failing heart, sCD146 may be released by veins in response to stretch induced by systemic congestion in HF. This study investigated the source, effects of vascular stress on release and prognostic properties of sCD146 in HF. METHODS: In a peripheral venous stress study, plasma concentrations of sCD146 and N-terminal probrain natriuretic-peptide (NT-proBNP) were measured in 44 HF patients at baseline and after 90 min of unilateral forearm venous congestion. In addition, sCD146 and NT-proBNP were measured in peripheral vein (PV) and coronary sinus (CS) blood samples of 137 HF patients and the transcardiac gradient was calculated. Those patients were followed for major adverse cardiovascular events (MACE) during 2 years. RESULTS: The induction of venous stress was associated with a pronounced increase in circulating concentrations of sCD146 in the congested arm (+60 μg/L) compared to the control arm (+16 μg/L, P = 0.025), while no difference in NT-proBNP concentrations was seen. In contrast to positive transcardiac gradient for NTproBNP, median sCD146 concentrations were lower in CS than in PV (396 vs 434, P < 0.001), indicating a predominantly extracardiac source of sCD146. Finally, increased PV concentrations of sCD146 were associated with higher risk of MACE at 2 years. CONCLUSIONS: Soluble CD146 is released from the peripheral vasculature in response to venous stretch and may reflect systemic congestion in chronic HF patients.

Original languageEnglish (US)
Pages (from-to)386-393
Number of pages8
JournalClinical chemistry
Issue number1
StatePublished - Jan 2017

Bibliographical note

Funding Information:
The European Commission's Seventh Framework program under grant agreement number 305507 (HOMAGE), the National Institute of Health (NIH grant number HL092144A), and the A. L. Mailman Family Foundation. A financial collaboration exists between MyCartis and Inserm. M. Arrigo, Fellowship of the Collège de Médecine des Hôpitaux de Paris; Q.A. Truong, NIH/NHLBI K23HL098370 and L30HL093896, St. Jude Medical and ACRIN; J. Szymonifka, NIH/NHLBI K23HL098370; J.L. Januzzi, Roche Diagnostics, Singulex, and Prevencio; J.P. Singh, St Jude Medical, Medtronic, BostonScientific, SorinGroup, Biotronik, BG Medicine, and Siemens.

Publisher Copyright:
© 2016 American Association for Clinical Chemistry.


Dive into the research topics of 'Soluble CD146 is a novel marker of systemic congestion in heart failure patients: An experimental mechanistic and transcardiac clinical study'. Together they form a unique fingerprint.

Cite this